A multicollaborative study has identified gaps in existing quality measures used by accountable care programs that could result in missed opportunities to improve patient outcomes.
A collaborative study by the National Pharmaceutical Council, Discern Health, the Duke-Margolis Center for Health Policy, and the American Society of Clinical Oncology (ASCO), identified gaps in existing quality measures used by accountable care programs that could result in missed opportunities to improve patient outcomes.
Discern Health analyzed gaps in accountable care measure sets for 10 cancer conditions: breast, chronic myelogenous leukemia, colon, kidney, melanoma, non-Hodgkin lymphoma (NHL), non-small cell lung (NSCLC), ovarian, pancreatic, and prostate cancer. These cancer types were selected based on several factors, including:
The authors identified measure gaps based on discrepancies between recommendations by the National Comprehensive Cancer Network treatment guidelines and the existing quality measures used by oncology-focused accountable care programs and those developed by professional organizations such as the National Quality Forum, ASCO, American College of Surgeons, and American Society for Radiation Oncology.
Their initial gap analysis flagged the following in measures used by the accountable care programs:
These results were subsequently presented to a panel of experts in cancer care, which included patient advocates, providers, payers, employers/purchasers, policy makers, and quality organization representatives. After reviewing the data, the experts recommended the following:
Based on their analysis, the participants laid out a few recommendations to organizations—including the Core Quality Measure Collaborative (a group led by America’s Health Insurance Plans and CMS), the Agency for Healthcare Research and Quality, and the Patient-Centered Outcomes Research Institute—to promote measure alignment and funding to develop these cross-cutting quality measures.
You can access the full study and recommendations here.